Why do people age? Why are aging-associated diseases steadily increasing? Through CECAD’s achievements, Cologne now holds a leading position in aging research, offering enormous possibilities for the development of innovative, therapeutic approaches to the challenges facing our aging society. Over 400 international renowned researchers form a well-linked, international and interdisciplinary team. They dynamically push forward research into the underlying causes of aging and aging-associated diseases such as neurodegenerative disorders, diabetes, strokes, kidney failure or cancer. CECAD sets a main focus on translational research. The entire research effort at the Cluster of Excellence CECAD is aligned to its bold vision: to unravel the molecular mechanisms underlying the aging process in order to develop novel therapies. Due to the systematic translation of experimental findings from basic research into clinical trials, new concepts emerge for novel clinical proceedings and therapies. The process reveals whether a research hypothesis established in the laboratory still holds true for clinical applications, bringing the realization of CECAD’s vision for a myriad of aging-associated diseases a step closer. Within the event "CECAD Research Meets BioRiver Companies" CECAD seeks the cooperation of suitable biotechnical or pharmaceutical partners for joint projects. Cooperation in different forms offers trend-setting possibilities for research.
Session I - 16:00-17:00
Introducing the potential of academic science
to the BioRiver companies
Prof. Dr. Carien Niessen, Head of CECAD Platform for Career Develop- ment & Gender Equality Prof. Dr. Oliver Cornely, Head of CECAD Translational Platform, Medical Director of the Clinical Trials Center of the University of Cologne
Session II - 17:00-17:50
Words of welcome
Prof. Dr. Dr. Thomas Krieg, Dean of the Medical Faculty of the University of Cologne, Member of the CECAD Executive Board
Translational Research challenges, needs and accomplishments within CECAD
Prof. Dr. Oliver Cornely
Introduction to CECAD
Prof. Dr. Thomas Benzing, Member of the CECAD Executive Board and Chairman of the Department II of Internal Medicine, University Hospital Cologne
Successful translational example
Prof. Dr. Thomas Benzing
Session III 18:00-18:50
Introduction to BioRiver e.V.
Dr. Jörg Vollmer, CEO, Nexigen GmbH, Member of the Board, BioRiver e.V. Since 2004, BioRiver – Life Science im Rheinland e.V. is fully committed to represent the Life Sciences sector in the bio-region Rhineland as an independent industry organization. Several international renowned biotech companies are associated under its roof, among them Qiagen and Miltenyi Biotec, Lonza or Taconic Artemis, and not at least Bayer AG as global pharmaceutical enterprise.
Short presentations of four companies
BioRiver member companies present fields of innovation and cooperation projects:
Session IV 18:50-20:00
Discussion and poster session, flying buffet
Scientists of CECAD and BioRiver companies
March 11, 2013, 16:00
Venue: Biocenter at the University of Cologne / Foyer, Zülpicher Str. 47b, 50674 Köln